Arax Advisory Partners’s Citius Pharmaceuticals CTXR Stock Holding History
Bought
Maintained
Sold
Other funds holding CTXR
MFS
XT
AAG
Arax Advisory Partners's CTXR Position: Q2 2026 in Review
Arax Advisory Partners opened a new position in Citius Pharmaceuticals (CTXR) in Q2 2026: 84 shares worth $51. The stake represents ﹤0.01% of the portfolio and ranks #5163 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in CTXR as recently as Q4 2025.
Arax Advisory Partners first reported a position in CTXR in Q3 2025 and has held it in 3 quarters since. The position peaked at $104 in Q3 2025. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.
- Arax Advisory Partners held 84 shares of Citius Pharmaceuticals worth $51 as of Q2 2026.
- Citius Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
- Citius Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5163 holding.
- Arax Advisory Partners first reported a position in Citius Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
- Arax Advisory Partners's Citius Pharmaceuticals position peaked at $104 in Q3 2025.
- 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.